Botulinum toxin therapy: a tempting tool in the management of salivary secretory disorders
| Autor: | Lorenzo Pignataro, Sara Torretta, Minorati D, Giuseppe Sambataro, Francesco Ottaviani, Cristina Nascimbene, Pasquale Capaccio, Maurizio Osio |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Adult
Male medicine.medical_specialty Sialography Salivary Gland Diseases Injections Intralesional Risk Assessment Severity of Illness Index Drug Administration Schedule Salivary Glands Drooling Humans Medicine Prospective Studies Botulinum Toxins Type A Sialoendoscopy Aged Paresis Aged 80 and over Dose-Response Relationship Drug medicine.diagnostic_test business.industry Sialorrhea Middle Aged Botulinum toxin Facial nerve Gustatory sweating Parotid gland Surgery Treatment Outcome medicine.anatomical_structure Otorhinolaryngology Patient Satisfaction Anesthesia Quality of Life Female medicine.symptom business Follow-Up Studies medicine.drug |
| Zdroj: | American Journal of Otolaryngology. 29:333-338 |
| ISSN: | 0196-0709 |
| Popis: | Purpose The aim of the study was to investigate the feasibility and effectiveness of botulinum toxin therapy in salivary secretory disorders. Materials and methods We treated 24 patients with botulinum neurotoxin type A for drooling, salivary fistulas, sialoceles, recurrent parotitis, and Frey's syndrome; each parotid gland and submandibular gland received 25 to 60 and 10 to 40 mouse units, respectively, per session. All the patients other than those with Frey's syndrome underwent, for diagnostic purpose, color Doppler ultrasonography (Hitachi H 21; frequency, 7.5 MHz, Scanner, Kashiwa, Japan), and Minor's test was carried out for gustatory sweating; pretreatment magnetic resonance sialography (Philips Gyroscan Intera, Eindhoven, The Netherlands) and sialoendoscopy were also performed in selected cases. The follow-up included clinical and ultrasonographic examinations and Minor's test. Results A clinical improvement was observed in all patients: complete clinical recovery in 12, subtotal in 6, and partial in 6. A self-assessment test suggested the cessation of sweating by the 10th day in most patients with Frey's syndrome. Botulinum toxin lost its effectiveness approximately after 4 months, requiring further administrations especially for drooling. No major side effects were observed with the exception of transitory paresis of the lower branch of the facial nerve in a patient with concomitant autonomic diabetic neuropathy. Conclusions Our findings suggest that botulinum toxin therapy is valid for the nonsurgical management of patients with salivary secretory disorders; the use of color Doppler ultrasonographic monitoring warrants the safety of the procedure. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect